<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22025" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Galactose-1-Phosphate Uridyltransferase Deficiency</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Los</surname>
            <given-names>Evan</given-names>
          </name>
          <aff>East Tennessee State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ford</surname>
            <given-names>George A.</given-names>
          </name>
          <aff>East Tennessee State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Evan Los declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>George Ford declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22025.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Galactosemia is an inborn error of metabolism due to impaired degradation of galactose. If not recognized and treated promptly, affected infants may develop significant morbidity within days of birth. Newborn screening tests in developed countries have helped identify affected infants early. However, providers must maintain a high index of suspicion in ill newborns as feeding intolerance, hepatomegaly, lethargy, coagulopathy, and renal dysfunction may occur within the first few days of life, even before newborn screening tests have been finalized. This activity reviews the workup of a patient with suspected galactosemia and the role of the interprofessional team in managing this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of galactosemia.</p></list-item><list-item><p>Summarize how galactosemia is diagnosed early.</p></list-item><list-item><p>Outline the signs and symptoms of galactosemia.</p></list-item><list-item><p>Review the workup of a patient with suspected galactosemia and the role of the interprofessional team in managing this condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22025&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22025">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22025.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Galactosemia is an inborn error of metabolism due to impaired degradation of galactose.&#x000a0;The disease was first described in&#x000a0;1917, and defective galactose metabolism was explained&#x000a0;as the cause in the 1950s. If not recognized and treated promptly, affected infants may develop significant morbidity within days of birth. Newborn screening tests in developed countries have helped identify affected infants early. However, providers must maintain a high index of suspicion in ill newborns as feeding intolerance, hepatomegaly, lethargy, coagulopathy, and renal dysfunction may occur within the first few days of life, even before newborn screening tests have been finalized.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref><xref ref-type="bibr" rid="article-22025.r2">[2]</xref><xref ref-type="bibr" rid="article-22025.r3">[3]</xref></p>
      </sec>
      <sec id="article-22025.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The <italic toggle="yes">GALT</italic> gene on chromosome 9p13 encodes for galactose-1-phosphate uridylyltransferase, which is responsible for metabolizing galactose-1-phosphate to UDP-galactose. Deficiency of the enzyme leads to classic galactosemia. The <italic toggle="yes">GALK1</italic> gene on chromosome 17q24 encodes for galactokinase, which is responsible for metabolizing galactose to galactose-1-phosphate. The&#x000a0;<italic toggle="yes">GALE</italic> gene on chromosome 1p36-p35 encodes for UDP-galactose 4-epimerase, which is responsible for metabolizing UDP-galactose to UDP-glucose for use in glycogenesis. Inheritance is autosomal recessive, so both parents must be carriers, and offspring have a 25% chance of having clinical symptoms. Carriers do not typically demonstrate symptoms.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref></p>
        <p>Duarte galactosemia is a variant of galactosemia due to diminished galactose-1-phosphate uridylyltransferase enzyme&#x000a0;activity (typically around 14% to 25%). Individuals born with Duarte variant&#x000a0;galactosemia are thought to be asymptomatic with or without dietary intervention, and&#x000a0;the consensus among health professionals is that affected&#x000a0;individuals&#x000a0;do not&#x000a0;require treatment. However, some reports to the&#x000a0;contrary exist, and no adequately powered study&#x000a0;has been completed to&#x000a0;verify&#x000a0;or refute the possible effects of diminished <italic toggle="yes">GALT</italic> activity&#x000a0;on long-term neurodevelopmental outcomes.&#x000a0;Duarte galactosemia may or may not be detected by newborn screening testing.<xref ref-type="bibr" rid="article-22025.r4">[4]</xref></p>
      </sec>
      <sec id="article-22025.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Approximately 1 in 19,000 to 44,000 infants&#x000a0;in Europe and the United States&#x000a0;have galactosemia. Still, the incidence is highly variable based on ethnic background, with the highest incidence in the Irish Traveler population of approximately 1 in 480. Inheritance is autosomal recessive.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref></p>
      </sec>
      <sec id="article-22025.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The disaccharide lactose found in breastmilk and most infant&#x000a0;formulas is metabolized to the monosaccharides glucose and galactose. In galactosemia, the enzymes needed for further galactose metabolism are deficient. Classic galactosemia is caused by galactose-1-phosphate uridylyltransferase (GALT) deficiency, whereas galactokinase and UDP-galactose epimerase deficiencies may cause similar clinical consequences by disrupting the normal galactose metabolism (see figure). Ultimately, levels of galactose-1-phosphate reach toxic levels, and galactose may be alternatively reduced to its sugar alcohol form, galactitol. Galactitol is thought to cause direct damage to tissues leading to hepatomegaly, cirrhosis, renal failure, feeding intolerance, vomiting, hypoglycemia, seizure, lethargy, intellectual impairment, and cataracts. Untreated, mortality is at least 75%. Even when treated from a young age, sequelae may include cognitive or behavioral impairment, speech difficulties, low bone mineral density, ataxia or tremors, and primary ovarian insufficiency or failure in most girls.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref></p>
      </sec>
      <sec id="article-22025.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Increased levels of galactose-1-phosphate due to blockage of the typical metabolic pathway are suspected to lead to alternative metabolism and direct tissue damage. Elevated levels of galactitol (galactose reduced to its sugar alcohol form) have been found in the urine of patients with galactosemia as well as tissues with evidence of damage in galactosemia. Galactose may also be oxidized to galactonate which may be a less toxic metabolite compared to accumulated galactitol.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref></p>
      </sec>
      <sec id="article-22025.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Infants with galactosemia will typically present within the first few days of life with jaundice, hepatomegaly, lethargy, and severe feeding intolerance once there is any exposure to dietary galactose in the form of breastmilk or most standard infant formulas. Additional findings may include&#x000a0;poor weight gain,&#x000a0;renal failure, coagulopathy, hypoglycemia, seizures, cerebral edema, cataracts, vitreous hemorrhage, neutropenia, and <italic toggle="yes">Escherichia&#x000a0;coli</italic> sepsis. Once diagnosed, long-term follow-up includes monitoring for cognitive and behavioral impairment, fine and gross motor delays, speech difficulties, low bone mineral density, ataxia or tremor, and primary ovarian insufficiency/failure.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref><xref ref-type="bibr" rid="article-22025.r5">[5]</xref></p>
      </sec>
      <sec id="article-22025.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Newborn screening tests will identify most cases of galactosemia in developed countries. Testing evaluates for pertinent enzyme activity levels so diagnosis can be made even if testing is done before the introduction of galactose in the diet. However, if a blood transfusion has occurred before newborn screening tests, a case may be misinterpreted as being normal due to the presence of normal enzyme activity in the transfused blood.</p>
        <p>Severe symptoms&#x000a0;often manifest&#x000a0;within the first several days of life, before newborn screening tests may be finalized. Thus, it is important for the practitioner to maintain a high index of suspicion for inborn errors of metabolism such as galactosemia when the newborn demonstrates feeding intolerance, lethargy, and other suspicious signs like hepatomegaly renal failure, cataracts, hypoglycemia, and seizures.</p>
        <p>If there is a known risk for galactosemia in a fetus, amniocentesis or chorionic villus sampling can make or exclude a diagnosis of galactosemia before delivery.</p>
        <p>Postnatal newborn screening is nearly universal in the United States and Europe. However, it should be noted that some populations with the highest incidence of galactosemia also may be less likely to deliver a baby in a hospital setting. GALT enzyme activity in red blood cells or GALT gene analysis should be performed in an infant suspected of having galactosemia.</p>
        <p>Long-term, annual screening of calcium and 25-hydroxyvitamin D is recommended with supplementation as necessary following age-specific recommendations for the general population.</p>
        <p>Biochemical monitoring is variable between treatment centers with most common assessments of blood galactose, RBC Gal-1-P, and/or urinary galactitol levels though it is unclear whether monitoring these levels is reflective of dietary adherence or correlates with clinical outcomes. Still, Gal-1-P levels are recommended at birth, 3 and nine months, and yearly.</p>
        <p>Assessment of developmental milestones, intellectual development, and speech and language assessment should be done at regular intervals such as toddler, pre-school, elementary, middle school, and high school ages. Assessment of executive function&#x000a0;using a standardized tool is recommended.</p>
        <p>Bone density should be assessed using bone densitometry starting around age eight to ten years and repeated every five years or sooner if low bone density is determined.</p>
        <p>If cataracts are found, a referral to an&#x000a0;ophthalmologist is appropriate.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref></p>
        <p>More than 80% of females with classic galactosemia have primary ovarian insufficiency.<xref ref-type="bibr" rid="article-22025.r6">[6]</xref><xref ref-type="bibr" rid="article-22025.r7">[7]</xref>&#x000a0;This should be discussed&#x000a0;before&#x000a0;the typical age of puberty, and referral to a pediatric endocrinologist is appropriate to discuss the timing and need for hormone testing as well as likely hormone replacement therapy, which usually continues until the age of menopause. Males with galactosemia tend to have a normal gonadal function. Counseling regarding reproductive options should be made available to girls with primary ovarian insufficiency.<xref ref-type="bibr" rid="article-22025.r8">[8]</xref><xref ref-type="bibr" rid="article-22025.r5">[5]</xref></p>
      </sec>
      <sec id="article-22025.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment is the total elimination of galactose from the diet. In infants, this means cessation of breastfeeding or standard infant formula feeding and transition to non-galactose-containing formula, typically a soy-based, casein hydrolysate, or&#x000a0;elemental&#x000a0;formula. Change in the diet should be made immediately and should not be delayed to await confirmatory testing. This dietary restriction of galactose is required throughout the lifetime, although some fruits, vegetables, legumes, unfermented soy-based products, and mature cheeses with minimal galactose content may be permissible. Currently, there is no enzyme replacement or other therapy available to allow for the safe intake of galactose.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref></p>
        <p>In Duarte variant galactosemia, there is a debate about whether galactose intake should be restricted. Physicians or parents may choose to restrict galactose intake in infancy and early childhood, though the benefits of doing&#x000a0;are uncertain.<xref ref-type="bibr" rid="article-22025.r4">[4]</xref></p>
      </sec>
      <sec id="article-22025.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Biliary atresia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fructose 1 phosphate aldolase deficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fanconi Bickel syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Galactose kinase deficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hemochromatosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hereditary fructose intolerance (HFI)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Portosystemic vascular shunts</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neonatal hemochromatosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22025.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Untreated severe classic galactosemia is a life-threatening disorder. Severely ill infants with galactosemia (e.g., those with sepsis, coagulopathy, liver dysfunction) may develop permanent liver, brain, and/or eye damage (although cataracts are often completely reversible).</p>
        <p>Most patients with severe galactosemia often do not survive the newborn period if treatment is not initiated.</p>
      </sec>
      <sec id="article-22025.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Even with the appropriate dietary therapy, most patients survive with at least 1-2 long-term complications. Almost all females with classic galactosemia present with hypergonadotropic hypogonadism/primary ovarian insufficiency (POI).&#x000a0;</p>
        <p>Severely ill infants with galactosemia (e.g., those with sepsis, coagulopathy, liver dysfunction) may develop permanent liver, brain, and/or eye damage (although cataracts are often completely reversible).</p>
        <p>Most patients with severe galactosemia often do not survive the newborn period if treatment is not initiated.</p>
      </sec>
      <sec id="article-22025.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Both parents and children should be involved in galactose-restricted dietary therapy. Milk is better tolerated in older patients, so the pros and cons of limiting milk intake should be discussed with patients.</p>
      </sec>
      <sec id="article-22025.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of galactosemia are best done with an interprofessional team that includes a pediatrician, geneticist, dietitian, social worker, primary care provider, pediatric nurse, and internist. The key is to eliminate galactose from the diet. In infants, this means cessation of breastfeeding or standard infant formula feeding and transition to non-galactose-containing formula, typically a soy-based, casein hydrolysate, or&#x000a0;elemental&#x000a0;formula. This dietary restriction of galactose is required throughout the lifetime, although some fruits, vegetables, legumes, unfermented soy-based products, and mature cheeses with minimal galactose content may be permissible. Currently, there is no enzyme replacement or other therapy available to allow for the safe intake of galactose.<xref ref-type="bibr" rid="article-22025.r1">[1]</xref></p>
        <p>The outcomes depend on the dietary compliance of the child. Today, there is continued debate about screening all newborns for this disorder.<xref ref-type="bibr" rid="article-22025.r3">[3]</xref><xref ref-type="bibr" rid="article-22025.r9">[9]</xref></p>
      </sec>
      <sec id="article-22025.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22025&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22025">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/galactose-1-phosphate-uridyltransferase-deficiency/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22025">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22025/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22025">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22025.s16">
        <title>References</title>
        <ref id="article-22025.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Welling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Burlina</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Eyskens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gautschi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;newald</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gubbels</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Knerr</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Labrune</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Portnoi</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>&#x000d5;unap</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Rubio-Gozalbo</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Timmers</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Treacy</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Van Calcar</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Waisbren</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>AM</given-names>
              </name>
              <collab>Galactosemia Network (GalNet)</collab>
            </person-group>
            <article-title>International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-176</page-range>
            <pub-id pub-id-type="pmid">27858262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22025.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yazdizadeh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nouhi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelishadi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Newborn screening for galactosaemia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Dec</month>
            <day>23</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD012272</fpage>
            <pub-id pub-id-type="pmid">29274129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22025.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosch</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Galactosaemia - should it be screened in newborns?</article-title>
            <source>Dev Period Med</source>
            <year>2018</year>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-224</page-range>
            <pub-id pub-id-type="pmid">30281516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22025.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Fridovich-Keil</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gambello</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Sharer</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <chapter-title>Duarte Variant Galactosemia</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2014</year>
            <month>12</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">25473725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22025.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cordeiro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Galactokinase deficiency: a treatable cause of bilateral cataracts.</article-title>
            <source>BMJ Case Rep</source>
            <year>2021</year>
            <month>Jun</month>
            <day>04</day>
            <volume>14</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">34088690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22025.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fridovich-Keil</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gubbels</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Land</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rubio-Gozalbo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Ovarian function in girls and women with GALT-deficiency galactosemia.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>357</fpage>
            <page-range>357-66</page-range>
            <pub-id pub-id-type="pmid">20978943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22025.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forges</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Monnier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leheup</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cheillan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brivet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbarino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gu&#x000e9;ant</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Feillet</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Ovarian tissue cryopreservation and subsequent spontaneous pregnancies in a patient with classic galactosemia.</article-title>
            <source>Fertil Steril</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>290.e1</fpage>
            <page-range>290.e1-3</page-range>
            <pub-id pub-id-type="pmid">20663501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22025.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubio-Gozalbo</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gubbels</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Menheere</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Wodzig</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Land</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Gonadal function in male and female patients with classic galactosemia.</article-title>
            <source>Hum Reprod Update</source>
            <year>2010</year>
            <season>Mar-Apr</season>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-88</page-range>
            <pub-id pub-id-type="pmid">19793842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22025.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stroek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bouva</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Schielen</surname>
                <given-names>PCJI</given-names>
              </name>
              <name>
                <surname>Vaz</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Heijboer</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>de Jonge</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boelen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for newborn screening for galactokinase deficiency: A systematic review and evaluation of Dutch newborn screening data.</article-title>
            <source>Mol Genet Metab</source>
            <year>2018</year>
            <month>May</month>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-56</page-range>
            <pub-id pub-id-type="pmid">29580649</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
